Medifast, Inc. (MED) Stock Forecast
MED analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 1 analysts
- Price target
- $12.00 average of analyst targets
- Upside to target
- +1.0% from the latest close
- Next earnings
- October 26, 2026 EPS estimate $-0.40
- 52-week range
- $9.45 – $13.15
MED analyst ratings
1 analystsNumber of analysts at each rating.
MED price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MED earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.35 | −$0.35 | −$0.21 | −66.7% | 1 |
| Current fiscal year (2026) | −$1.15 | −$1.15 | −$1.15 | −$1.70 | +32.4% | 1 |
| Next fiscal year (2027) | −$0.28 | −$0.28 | −$0.28 | −$1.15 | +75.6% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MED revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $71.3M | $71.3M | $71.3M | −20.2% | 1 |
| Current fiscal year (2026) | $287.7M | $287.7M | $287.7M | — | 1 |
| Next fiscal year (2027) | $273.7M | $273.7M | $273.7M | −4.9% | 1 |
MED EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MED revenue: reported and forecast
MED EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.62 | −$0.62 | −$0.62 | −$0.62 | −$0.35 | −43.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.85 | −$1.85 | −$1.85 | −$1.85 | −$1.15 | −37.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.60 | −$0.60 | −$0.60 | −$0.60 | −$0.28 | −53.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MED earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MED beat in 8 of 12.
What analysts expect from MED
1 analysts cover Medifast; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.00, 1.0% above the latest close of $11.88. Analysts expect earnings of −$1.15 per share for 2026, +32.4% from a year earlier. For 2027 the average estimate is −$0.28 per share on revenue of $273.7 million. Medifast beat the EPS estimate in 8 of the last 12 quarters.
Related: MED income statement, MED key metrics, MED chart. See the MED stock overview for the latest quote and news.
MED forecast FAQ
What is Medifast's price target?
The average analyst price target for Medifast is $12.00, 1.0% above the latest close of $11.88.
Is Medifast a buy, hold or sell?
Of 1 analysts covering Medifast, 0 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Medifast's EPS forecast?
Analysts forecast −$1.15 per share for 2026 (range −$1.15 to −$1.15); for 2027 the estimate is −$0.28.
What is Medifast's revenue forecast?
The average revenue estimate for 2026 is $287.7 million; for 2027 it is $273.7 million.
When does Medifast report earnings?
Medifast is expected to report results for the quarter ending September 30, 2026 on October 26, 2026 before the market opens; the EPS estimate is $-0.40.
Does Medifast usually beat earnings estimates?
Medifast reported EPS at or above the analyst estimate in 8 of the last 12 quarters.